A Phase 2 interventional study of Psilocybin and Placebo in Alcohol Use Disorder, sponsored by Clairvoyant Therapeutics. Active, not recruiting at 12 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Clairvoyant Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing psilocybin in Alcoholism — 8 open to participants now, 13 under way, 1 of them phase 3. Psilocybin · Alcoholism.
Among the 17 studies testing psilocybin in Alcoholism, this one is the 3rd largest by planned enrollment, is the only one that started in 2022, is one of 16 in phase 2, reaches primary completion later than 1 of the 12 other live ones, and was the 8th registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →8 of the 17 studies testing psilocybin in Alcoholism are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18–65
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of Iowa · Sites in United States
Ages 21–65
University of Calgary · Sites in Canada
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 128 is above the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 62 across the 17 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 17 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Clairvoyant Therapeutics as lead sponsor.
Clairvoyant Therapeutics has 1 study filed under Alcoholism — fewer than ten, so there is no comparison to draw.
1 of the studies testing psilocybin in Alcoholism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05995769University of CalgaryPsilocybin-Assisted Psychotherapy for Alcohol Use Disorder | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing psilocybin in Alcoholism, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (AUD). The main question[s] it aims to answer are:
Participants will
Researchers will compare psilocybin and placebo groups to see if alcohol consumption is decreased.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 oral doses of 25mg psilocybin capsules
Drug: Psilocybin
2 oral doses of placebo (microcrystalline cellulose) capsules
Drug: Placebo
Psilocybin and psychotherapy
Placebo and psychotherapy
Reduction in the number of Heavy Drinking Days
Mean number of HDD from V5 (baseline) measured monthly (4 weeks) over the treatment period (Week 8), where heavy drinking is defined as the consumption of ≥60 g alcohol/day (if male) or ≥40 g alcohol/day (if female).
Time frame: 8 weeks
Started May 2022 (actual). Primary completion is estimated for Aug 2024, 27 months after the start.
Of 134 phase 2 interventional studies under Alcoholism, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin